Tag Archives: T-VEC

June, 2015

  • 2 June

    Amgen and Roche Team up on Cancer Immunotherapy Study

    Amgen and Roche have teamed up to test combining their investigational immunotherapies for patients with breast and colorectal cancer. The companies said that they have formed a collaboration on a Phase Ib study to evaluate the safety and efficacy of Amgen’s investigational oncolytic immunotherapy, talimogene laherparepvec (T-VEC), in combination with …

May, 2015

  • 1 May

    FDA Panel Recommends Approval of Amgen’s T-Vec in Melanoma

    This week the US Food and Drug Administration (FDA) shared its concerns about the design of Amgen’s study evaluating its experimental melanoma treatment, talimogene laherparepvec (T-VEC), however this did not sway the agency’s advisory panel, which voted overwhelmingly in favor of the drug candidate. The agency’s independent Oncologic Drugs Advisory …